Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover

      This paper is only available as a PDF. To read, Please Download here.


      We studied the effect of probucol on lipoprotein composition and VLDL apo B turnover. In 7 hypercholesterolemic subjects, probucol therapy lowered mean total cholesterol, HDL cholesterol and HDL triglycerides, raised LDL triglycerides and did not change LDL cholesterol. LDL cholesterol: LDL triglycerides mass ratios fell. In all 6 subjects studied by rate-zonal ultracentrifugation, the flotation rate of LDL decreased. The isolated LDL were depleted of cholesteryl esters relative to protein. Thus, there were changes in the physical and chemical properties of LDL. All 6 subjects had reductions in HDL2, with variable changes in HDL3 on zonal ultracentrifugation. Probucol did not cause significant alterations in VLDL apo B turnover in 4 patients. The results suggest that the alterations in HDL probably are not related to changes in the flux of VLDL plasma, but rather may be due to direct effects of the drug on HDL production or catabolism.



      Apo A-I, A-II, B = apolipoprotein A-I, A-II, B (), HDL = high density lipoproteins (), IDL = intermediate density lipoproteins (), LDL = low density lipoproteins (), RIA = radioimmunoassay (), TMU = tetramethylurea (), VLDL = very low density lipoproteins ()
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • LeLorier J.
        • DuBreuil-Quidoz S.
        • Lussier-Cacan S.
        • Huang Y.
        • Davignon J.
        Diet and probucol in lowering cholesterol concentrations.
        Arch. Int. Med. 1977; 137: 1429
        • Riesen W.F.
        • Keller M.
        • Mordasini R.
        Probucol in hypercholesterolemia — A double blind study.
        Atherosclerosis. 1980; 36: 201
        • Mellies M.
        • Cartside P.
        • Glatfelter L.
        • Vink P.
        • Guy G.
        • Schonfeld G.
        • Glueck C.
        Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apoproteins AI and AII in adults with primary familial hypercholesterolemia.
        Metabolism. 1980; 29: 956
        • Hunninghake D.
        • Bell C.
        • Olson L.
        Effect of probucol on plasma lipids and lipoproteins in type Ilb hyperlipoproteinemia.
        Atherosclerosis. 1980; 37: 469
        • Miettinen T.A.
        Mode of action of a new hypocholesterolemic drug (DH-581) in familial hypercholesterolemia.
        Atherosclerosis. 1972; 15: 163
        • Nestel P.J.
        • Billington T.
        Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis.
        Atherosclerosis. 1981; 38: 203
        • Miettinen T.A.
        • Huttunen J.K.
        • Kuusi T.
        • Kumlin T.
        • Mattila S.
        • Naukkarinen V.
        • Strandberg T.
        Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase.
        Clin. Chim. Acta. 1981; 113: 59
        • Patsch J.R.
        • Gotto A.M.
        • Olivecrona T.
        • Eisenberg S.
        Formation of high density lipoprotein like particles during lipolysis of very low density lipoproteins in vitro.
        in: Proc. Nat. Acad. Sci. (USA). 75. 1978: 4519
        • American Heart Association Communications Division
        The Way to a Man's Heart booklet, 51 018-A.
        1972 (Dallas, TX)
        • McFarlane A.S.
        Efficient trace-labelling of proteins with iodine.
        Nature (Lond.). 1958; 182: 53
        • Kane J.P.
        • Sata T.
        • Hamilton R.L.
        • Havel R.J.
        Apoprotein composition of very low density lipoproteins of human serum.
        J. Clin. Invest. 1975; 56: 1622
        • Bensadoun A.
        • Weinstein D.
        Assay of proteins in the presence of interfering materials.
        Anal. Biochem. 1976; 70: 241
        • Margolis S.
        • Langdon R.G.
        Studies on human serum β1-lipoproteins, Part 1 (Amino acid composition).
        J. Biol. Chem. 1966; 241: 469
        • Le N.
        • Melish J.S.
        • Roach B.
        • Ginsberg H.N.
        • Brown W.V.
        Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins.
        J. Lipid Res. 1978; 19: 578
        • Sigurdsson G.
        • Nicoll A.
        • Lewis B.
        Conversion of very low density lipoprotein to low density lipoprotein, a metabolic study of apolipoprotein B kinetics in human subjects.
        J. Clin. Invest. 1975; 56: 1481
        • Zilversmit D.B.
        • Entenman C.
        • Fishler M.C.
        On the calculation of ‘turnover time’ and ‘turnover rate’ from experiments involving the use of labeling agents.
        J. Gen. Physiol. 1942; 26: 325
        • Patsch J.R.
        • Sailer S.
        • Kostner G.
        • Sandhofer F.
        • Holasek A.
        • Braunsteiner H.
        Separation of the main lipoprotein density classes from human plasma by rate-zonal ultracentrifugation.
        J. Lipid Res. 1974; 15: 356
        • Patsch W.
        • Schonfeld G.
        • Gotto A.M.
        • Patsch J.R.
        Characterization of human high density lipoproteins by zonal ultracentrifugation.
        J. Biol. Chem. 1980; 225: 3178
      1. Manual of Laboratory Operations, Lipid Research Clinics Program. National Heart and Lung Institute, Bethesda, MD1974 (DHEW Publication No. NIH 75-628)
        • Patsch W.
        • Sailer S.
        • Braunsteiner H.
        An enzymatic method for the determination of the initial rate of cholesterol esterification in human plasma.
        J. Lipid Res. 1976; 17: 182
        • Eisenberg S.
        • Bilheimer D.W.
        • Levy R.I.
        • Lindgren F.T.
        On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.
        Biochim. Biophys. Acta. 1973; 326: 361
        • Schonfeld G.
        • Witztum J.
        • Basich P.
        Probucol further lowers the serum cholesterol of colestipoltreated patients with hypercholesterolemia.
        Artery. 1982; 10: 99
        • Opplt J.J.
        • Bahler R.C
        Ultracentrifugal study of metabolic effects of probucol — Plasma lipoproteins in patients with proven coronary artery disease.
        Artery. 1982; 10: 108